Curis CRIS
NASDAQ CRIS
$1.20 -0.07 (-5.51%)
At close: Sep 9, 2026 · 4:00 PM EDT

Curis (CRIS) Share-based Compensation (2010 - 2026)

Curis' (CRIS) quarterly Share-based Compensation came in at $569000.0 in Q2 2026, down 49.87% on a YoY basis from $1.1 million in Q2 2025, and down 1.04% quarter-over-quarter from $575000.0 in Q1 2026.

Analysis

Curis (CRIS) Share-based Compensation (2010 - 2026) Analysis & Trends

Curis (CRIS) has reported Share-based Compensation for 17 consecutive years, with $569000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Share-based Compensation fell 49.87% year-over-year to $569000.0; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (down 42.31% YoY), and the FY2025 full-year result was $4.0 million, down 32.21% from the prior year.
  • Share-based Compensation fell to $569000.0 in Q2 2026 per CRIS's latest filing, from $575000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.0 million in Q2 2022 and bottomed at $569000.0 in Q2 2026.
  • Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $1.4 million in 2023.
  • The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 56.32% in 2022, then plunged 50.6% in 2026.
  • Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then fell by 11.24% to $1.5 million in 2023, then declined by 17.31% to $1.3 million in 2024, then sank by 37.89% to $795000.0 in 2025, then retreated by 28.43% to $569000.0 in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $569000.0, $575000.0, and $795000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 86.63 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 83.34 Mn
10 Curis 2.57 Mn -3.05 Mn - 569,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 569,000.00
Mar 31, 2026 575,000.00
Dec 31, 2025 795,000.00
Sep 30, 2025 924,000.00
Jun 30, 2025 1.14 Mn
Mar 31, 2025 1.16 Mn
Dec 31, 2024 1.28 Mn
Sep 30, 2024 1.38 Mn
Jun 30, 2024 1.70 Mn
Mar 31, 2024 1.56 Mn
Dec 31, 2023 1.55 Mn
Sep 30, 2023 1.63 Mn
Jun 30, 2023 1.42 Mn
Mar 31, 2023 1.40 Mn
Dec 31, 2022 1.74 Mn
Sep 30, 2022 1.32 Mn
Jun 30, 2022 1.97 Mn
Mar 31, 2022 1.72 Mn
Dec 31, 2021 1.44 Mn
Sep 30, 2021 1.46 Mn